LGALS3BP

Across TCGA pan-cancer cohorts, LGALS3BP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LGALS3BP data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LGALS3BP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS3BP expression acts as an unfavorable survival marker.

CCRCC, PDAC, and COAD are the cancer types where LGALS3BP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.377	0.755	<.001	73	view →
PDAC	OS	Quartile	All	0.423	0.694	.001	55	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	DFS	Tertile	All	0.596	0.792	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LGALS3BP–CCRCC (DFS)

Open the CCRCC breakdown →